Study Design

Error message

Deprecated function: The each() function is deprecated. This message will be suppressed on further calls in FieldCollectionItemEntity->fetchHostDetails() (line 272 of /var/www/development/merrimackXXX/site/sites/all/modules/contrib/field_collection/field_collection.module).

This is a randomized open-label, phase 2 study designed to evaluate PFS (primary endpoint) between the experimental and comparator arms within two distinct HER2 IHC groups.  Patients with advanced HER2-expressing distal esophagus, GE junction or stomach cancers who have failed one standard fluoropyrimidine/platinum-based frontline systemic therapy (with or without trastuzumab) in the Traditional HER2 Group, or without trastuzumab in the Non-Traditional HER2 Group are eligible.  A schematic representation of the study design is presented in Figure 11. 

Figure 11. Study Design 

studydesign.JPG

Related Content

ClinicalTrials.gov MM-111 Gastric/GEJ Cancer